IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
UP-0779249
(2007-07-17)
|
등록번호 |
US-7781442
(2010-09-13)
|
발명자
/ 주소 |
- Cheng, Soan
- Comer, Daniel D.
- Mao, Long
- Balow, Guity P.
- Pleynet, David
|
출원인 / 주소 |
- Neurogenetic Pharmaceuticals, Inc.
|
대리인 / 주소 |
|
인용정보 |
피인용 횟수 :
10 인용 특허 :
52 |
초록
Novel compounds, compositions, and kits are provided. Methods of modulating Aβ levels, and methods of treating a disease associated with aberrant Aβ levels are also provided.
대표청구항
▼
What is claimed is: 1. A method for treating amyloidosis associated with aberrant Aβ levels, said method comprising administering to a subject in need thereof an effective amount of a compound having a structure corresponding to Formula (VII): (A1-LA1)0-1-(B1)-LB1-(C1)-LC1-(D1)
What is claimed is: 1. A method for treating amyloidosis associated with aberrant Aβ levels, said method comprising administering to a subject in need thereof an effective amount of a compound having a structure corresponding to Formula (VII): (A1-LA1)0-1-(B1)-LB1-(C1)-LC1-(D1) (VII) and pharmaceutically acceptable salts thereof, wherein: A1 is an optionally substituted 1,3-imidazole or a 1,2,3-triazole; B1 is an optionally substituted phenyl or pyridyl; C1 is an optionally substituted thiazole; D1 is a substituted aryl; LA1 is a covalent bond; LB1 is a covalent bond; and LC1 is an amino linker linked at the 2-position of the thiazole. 2. The method of claim 1 wherein A1 is an optionally substituted 1,3-imidazole. 3. The method of claim 1 wherein said optionally substituted 1,3-imidazole is a methyl-substituted 1,3-imidazole. 4. The method of claim 1 wherein said methyl-substituted 1,3-imidazole is 4-methyl 1,3-imidazole. 5. The method of claim 1 wherein B1 is an optionally substituted phenyl. 6. The method of claim 1 wherein said optionally substituted phenyl is fluoro- or methoxy-substituted phenyl. 7. The method of claim 1 wherein B1 is an optionally substituted pyridyl. 8. The method of claim 1 wherein C1 is a thiazole. 9. The method of claim 1 wherein D1 is a di- or tri-alkyl substituted phenyl. 10. The method of claim 1 wherein D1 is 2,4-dimethyl-5-ethyl phenyl or 2-methyl-4-methoxy-5-isopropyl phenyl. 11. The method of claim 1 wherein said amyloidosis is a condition in which deposition of amyloid in the brain or periphery is a characteristic. 12. The method of claim 11 wherein said amyloidosis is associated with rheumatic diseases, idiopathic diseases, inherited conditions, inflammatory conditions, infectious diseases and malignancies. 13. The method of claim 11 wherein said amyloidosis is associated with Alzheimer's disease, Down's syndrome, HCHWA-D, familial amyloid polyneuropathy, familial amyloid cardiomyopathy (Danish type), isolated cardiac amyloid, amyloid angiopathy, systemic senile amyloidosis, familial systemic amyloidosis, light-chain amyloidosis (AL), dialysis-associated amyloidosis, renal amyloidosis, prion-related encephalopathies, spinal and spinobulbar muscular atrophy, atrial amyloidosis or pituitary amyloidosis. 14. The method of claim 1 wherein said amyloidosis is associated with Alzheimer's disease. 15. The method of claim 1 wherein said amyloidosis is associated with Down's syndrome. 16. The method of claim 1 wherein said amyloidosis is associated with diffuse Lewy body disease. 17. The method of claim 1 wherein said amyloidosis is associated with cerebral amyloid angiopathy (CAA). 18. The method of claim 1 wherein said amyloidosis is associated with systemic senile amyloidosis. 19. The method of claim 1 wherein said amyloidosis is associated with a prion-related encephalopathy. 20. The method of claim 1 wherein said amyloidosis is associated with mild cognitive impairment (MCI). 21. A method for treating a disease selected from Alzheimer's disease, Down's syndrome, HCHWA-D, familial amyloid polyneuropathy, familial amyloid cardiomyopathy (Danish type), isolated cardiac amyloid, amyloid angiopathy, systemic senile amyloidosis, familial systemic amyloidosis, light-chain amyloidosis (AL), dialysis-associated amyloidosis, renal amyloidosis, prion-related encephalopathies, spinal and spinobulbar muscular atrophy, atrial amyloidosis or pituitary amyloidosis, said method comprising administering to a subject in need thereof an effective amount of a compound having a structure corresponding to Formula (VII): (A1-LA1)0-1-(B1)-LB1-(C1)-LC1-(D1) (VII) and pharmaceutically acceptable salts thereof, wherein: A1 is an optionally substituted 1,3-imidazole or a 1,2,3-triazole; B1 is an optionally substituted phenyl or pyridyl; C1 is an optionally substituted thiazole; D1 is a substituted aryl; LA1 is a covalent bond; LB1 is a covalent bond; and LC1 is an amino linker linked at the 2-position of the thiazole.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.